Siva Therapeutics add key Business and Scientific Advisors

BOULDER, COLORADO, September 1, 2012–Siva Therapeutics has added two prestigious advisors to it team – one each to the Business and Scientific Advisory Boards.

Ron Eller, an experienced CEO/general manager with a demonstrated track record in turnarounds and in building teams that grow businesses, has joined our Business Advisory Board. Mr. Eller presently serves on the boards of directors of Next I/O, Inc., Solera National Bancorp, and the Colorado Neurological Institute. He also runs his own management consulting and investment firm, Monroe Street Capital, LLC and is a principal with a private equity firm, Top Rock, LLC. In February 2012 he stepped down as President and CEO of Ascent Solar Technologies, Inc., a NASDAQ-listed thin film photovoltaic manufacturer on whose board he had served since 2009 and CEO since 2011. From 1994 to 2008, Mr. Eller held various senior executive positions at Hewlett-Packard Company and one of its predecessor companies, Compaq Computer Corporation. He was part of the M&A team at Compaq, looking at many companies and completing seven acquisitions and one divestiture. He has significant experience as a management consultant advising companies in various industries on merger and acquisition, strategy, corporate performance and corporate governance matters. He has previously served on a number of private company, non-profit, and advisory boards in healthcare, capital markets, economic development, airport design, education, services, and investments / insurance. He holds a B.S. in aviation technology from Purdue University and an M.S. in business from Colorado State University, is a licensed commercial pilot, and is a Certified Public Accountant.

Mark W. Dewhirst, DVM, PhD, the Gustavo S. Montana Professor of Radiation Oncology and Director of the Radiation Oncology Program of the Duke Comprehensive Cancer Center, has joined our Scientific Advisory Board. Dr. Dewhirst holds appointments in the Departments of Pathology and Biomedical Engineering at Duke and in the Department of Anatomy Pathology and Radiology at the School of Veterinary Medicine at North Carolina State University. Dr. Dewhirst joined the faculty of Duke University in 1984, was promoted to Full Professor in 1993, and received an endowed professorship in 2002. For many years, Dr. Dewhirst directed a clinical program grant that studied the use of hyperthermia in the treatment of cancer. This program had four main themes: (1) Establishment of robust methods to measure hyperthermia treatment delivery (i.e. thermal dosimetry); (2) Investigation of novel therapeutic opportunities afforded by the use of hyperthermia; (3) Conducting human clinical trials testing the value of hyperthermia when combined with radiation and/or chemotherapy; and (4) understanding the physiologic and metabolic consequences of hyperthermia treatment. A recipient of the 2001 Wayne Rundles Award from the Duke Comprehensive Cancer Center, and the Failla Award and Lecture from the Radiation Research Society in 2008, Dr. Dewhirst has over 400 peer-reviewed publications, book chapters and reviews, and he is Editor-in-Chief of the International Journal of Hyperthermia. He currently serves on the Editorial Boards of several journals including Cancer Research, Clinical Cancer Research and the International Journal of Radiation Oncology Biology and Physics. He graduated from the University of Arizona in 1971 with a degree in Chemistry and Colorado State University in 1975 and 1979 with DVM and PhD degrees, respectively.

“We are delighted to have Ron and Mark join our advisory teams,” said Len Pagliaro, PhD, CEO of Siva. “Both are world-class leaders in their fields, and they bring invaluable breadth and depth to Siva. Their expertise will be critical for Siva’s next phase of growth.” 

About Siva Therapeutics Inc

Siva Therapeutics Inc is an early stage biotechnology company developing a photothermal device cancer therapy which uses heat to irreversibly damage solid tumor tissue. The heat is delivered to tumors by infrared light that is absorbed by gold nanoparticles and re-emitted as heat. The size, shape, and surface chemistry of the particles target the leaky vasculature of solid tumors, and the selective thermal sensitivity of tumor tissue enables the therapy to deliver clean margins. Siva therapy promises to be extremely safe, effective, and competitive in cost relative to surgery, chemotherapy, and radiation for cancer treatment. For more information please visit:

Media Contact:

PDF version of this article: August 31, 2012 – Siva Therapeutics adds Key Business and Scientific Advisors